Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms
Authors
Keywords
Myeloproliferative neoplasms, <em class="EmphasisTypeItalic ">JAK2</em>V617F, HDAC, Ruxolitinib, Vorinostat, Combination therapy
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-22
DOI
10.1007/s10637-019-00794-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
- (2019) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)
- (2018) Lianbin Yao et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis
- (2018) Lucia Masarova et al. BLOOD
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat
- (2017) Lianbin Yao et al. JOURNAL OF MEDICINAL CHEMISTRY
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
- (2013) Christen L. Andersen et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease
- (2013) E. Evrot et al. CLINICAL CANCER RESEARCH
- Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
- (2013) Meng Ling Choong et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- Efficacy of vorinostat in a murine model of polycythemia vera
- (2012) H. Akada et al. BLOOD
- Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
- (2012) Donna M. Weber et al. Clinical Lymphoma Myeloma & Leukemia
- Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
- (2012) J. Mascarenhas et al. CURRENT MEDICINAL CHEMISTRY
- Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- (2012) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK/STAT signaling in hematological malignancies
- (2012) W Vainchenker et al. ONCOGENE
- Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms
- (2011) Vibe Skov et al. LEUKEMIA & LYMPHOMA
- Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
- (2011) John Mascarenhas et al. Clinical Epigenetics
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
- (2009) Y. Wang et al. BLOOD
- Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms
- (2009) Lizz F. Grimwade et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Enhanced histone deacetylase enzyme activity in primary myelofibrosis
- (2008) Jen Chin Wang et al. LEUKEMIA & LYMPHOMA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started